Sentences with phrase «docetaxel patients»

There was one treatment - related death in the erlotinib group, and 22.1 % of docetaxel patients and 29.0 % of erlotinib patients suffered adverse events that led to dose modification.

A total of 27 % of docetaxel patients had grade 3 or 4 neutropenia, and 29 % had alopecia of any grade; 14 % of erlotinib patients suffered grade 3 or 4 dermatological toxicities.

Almost 72 % of docetaxel patients were current or former smokers, compared with 81.7 % in the erlotinib group.

Not exact matches

Researchers randomly selected 135 patients to receive nivolumab, sold under the name Opdivo, and 137 others to receive the chemotherapy drug docetaxel.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

If prolongation of life was the primary therapeutic objective and the patients were eligible for docetaxel treatment, the G - BA specified docetaxel in combination with prednisone or prednisolone as appropriate comparator therapy (docetaxel population).

The next generation drug in the taxane family, cabazitaxel, was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.

This was offset by a hint of considerably greater harm from radium - 223 + BSC due to more frequent, but never severe, diarrhea in patients without docetaxel pretreatment.

It was assumed in the assessment that most of the remaining patients actively decided against docetaxel treatment.

The majority of patients included in the study were not eligible for docetaxel because their disease had progressed despite pretreatment with this drug (approximately 57 %).

If docetaxel treatment was not an option for the patients or if the primary treatment goal was the relief of symptoms, the so - called «symptom control,» and the prevention of complications, the G - BA specified BSC as appropriate comparator therapy (BSC population).

No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal.

Patients were randomised 1:1 to receive therapy with ceritinib or chemotherapy (pemetrexed or docetaxel).

Results also showed 27.7 percent of patients in the ADT plus docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.

«When we embarked on this study, early clinical trials and laboratory studies supported the possibility (or hypothesis) that earlier therapy in appropriate patients with docetaxel, used in combination before hormonal resistance occurred, could have greater benefit, but required proof in a definitive study.

Results showed an increased survival of 13.6 months for patients treated with ADT plus docetaxel than with ADT alone.

It included 790 patients (median age of 63 years) who were enrolled and randomized from July 2006 to November 2012 to receive either ADT plus docetaxel every three weeks for six cycles or ADT alone.

In the ADT - plus - docetaxel group, 45 patients whose disease progressed received additional docetaxel.

In the ADT - only group, 124 patients were given docetaxel when their cancer worsened.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

The new analysis extends follow - up significantly; it includes 790 patients randomized to either ADT alone (393 patients) or in combination with docetaxel (397 patients).

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

Patients received 3 cycles of docetaxel at either 80 mg / m2 or 100 mg / m2 and trastuzumab three times a week followed by 3 cycles of chemotherapy.

Disease - free survival was similar in the 9 - week and 12 - month arms among those patients who received 100 mg / m2 docetaxel.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.

However, subset analyses of phase III trials suggest that patients with EGFR mutation - positive NSCLCs do not benefit from immunotherapy compared with docetaxel.

Patient 2 was diagnosed with widespread metastatic prostate cancer in 2013 and progressed on numerous systemic therapies, including leuprolide, bicalutamide, enzalutamide, abiraterone, and eventually docetaxel.

The BMS trial, called Checkpoint - 017, randomized 272 patients to receive either nivolumab intravenously every two weeks or the chemotherapy drug docetaxel intravenously every three weeks.

The median age of patients was similar between the two groups, at 67 in the docetaxel group and 66 in the erlotinib group.

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).

A total of 28.9 % of patients receiving docetaxel had not progressed after 6 months, compared with 16.9 % of erlotinib patients.

The drug's manufacturer, Roche, said trials in these patients have shown that giving pertuzumab in combination with the drugs trastuzumab (Herceptin) and docetaxel could extend survival by nearly 16 months compared to standard treatment.

For both populations, though, disease prognosis remains poor: the median progression - free survival for docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinib.

In 2014, researchers at the National Cancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast cancer].